ALJ Julius Locks in August 17th Filing Deadline | TTB Presented by Flowhub

In our latest Trade to Black podcast presented by Flowhub, Shadd Dales and Anthony Varrell kick off the week — starting with Organigram (TSX: OGI / NASDAQ: OGI) and their latest business update. The company released new details on early Sanity platform performance and updated Canadian market‑share positioning, giving a clearer look at how they’re setting up for the next phase of growth. Then in Segment #1, Dr. Dan Karlin, Chief Medical Officer of Definium Therapeutics (NASDAQ: DFTX) joins the show. Dr. Karlin breaks down exactly where Definium stands in its current clinical trial program, why their data is considered among the strongest in the psychedelic space, and how the industry is lining up for potential FDA approvals and commercialization beginning in 2027. We also get his reaction to last week’s headline‑making acquisition involving Eli Lilly (NYSE: LLY) purchasing AtaiBeckley (NASDAQ: ATAI) — a move that signals growing interest from major pharmaceutical players in psychedelic therapeutics. For Segment #2 we bring in Michael Bronstein, President of the American Trade Association for Cannabis and Hemp, to walk through the updated regulatory timeline now that the DEA’s rescheduling hearing has concluded. Administrative Law Judge Derek C. Julius has set August 17 as the deadline for all final briefs. Michael explains what that date actually means, how the process unfolds after August 17, and whether an ALJ Recommended Decision could realistically arrive before the end of August. Like, subscribe and leave your comments! 00:00:00 ALJ Julius sets August 17 cannabis filing deadline 00:02:10 World Cup talk LeBron sweepstakes and cannabis stock doldrums 00:03:45 Why August 17 matters and the endless cannabis waiting game 00:05:40 Organigram’s Germany update and Sanity Group performance 00:06:40 Cantor initiates Trulieve overweight and market skepticism 00:07:25 Bell ringing dates Glass House and AdvisorShares on NYSE 00:08:20 Introducing Definium Therapeutics and DT120 LSD program 00:12:00 Psychedelics efficacy data and massive unmet mental health need 00:18:10 Global commercialization strategy and psychiatry’s readiness to adopt 00:22:40 How Definium uses AI in clinical trial quality control 00:32:55 Breaking down the ALJ process and expectations for August 17 00:51:40 Hemp loophole November 12 ban risk and farm bill politics #CannabisIndustry #MSOS #CannabisStocks #CannabisNews #CannabisRescheduling #PsychedelicStocks #FDA #BigPharma #MentalHealth #Trump #ALJHearing #ALJTimeline #PsychedelicMedicine #DEARescheduling Want to see more Cannabis Reform? 🎬    • Why Cannabis Companies Are Backing Trump |...   🎬    • The DEA Hearing Is Over. Now What? | TDR C...   🎬    • Are THC Drinks Replacing Alcohol? | TDR Ca...   🎬    • DEA Hearing Ends: What Happens Next? | TDR...   Want to stay updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked newsletter: https://newsletter.thedalesreport.com... Find us on social media and podcast platforms: ✅ Facebook:   / thedalesreport   ✅ Twitter:   / thedalesreport   ✅ Instagram:   / dalesreport   ✅ LinkedIn:   / the-dales-report   Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon... Spotify: https://tinyurl.com/TDRTradeToBlackon... Website: https://thedalesreport.com/ For copyright matters, contact: [email protected] Podcast Disclaimer (Financial Interests) The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice. The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions. By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions made based on the information discussed. Full Disclosures: https://thedalesreport.com/website-te...